BMS eyes filings for myeloma ‘celmod’ iberdomide
Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after reporting positive results in a phase 3 trial. Full data from the EXCALIBER-RRMM study in relapse/refractory multiple myeloma is not ready to be disclosed, but BMS said the trial showed that the cereblon…